Weight-loss medicines approved by the MHRA (UK)

What MHRA approved means, which medicines are licensed in the UK for weight management, and why authorisation does not guarantee access.

If you are researching weight-loss medicines in the UK, it is easy to assume that approved by the MHRA means you can automatically get a treatment on the NHS or from any private provider. That is not how it works.

In the UK, MHRA authorisation means a medicine has been licensed for specific uses, with defined dosing, safety information, and prescribing boundaries.

It does not mean automatic NHS availability, automatic private suitability, or appropriate use outside the licensed indication.

Quick answer

MHRA authorisation means a medicine is licensed for specific uses in the UK. For weight management, the main MHRA-authorised GLP-1 or related options referenced by MHRA safety guidance are Wegovy (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide).

But being licensed does not mean you can automatically access it:

• NHS access depends on NICE guidance and local delivery pathways.
• Private access still depends on proper clinical assessment and prescribing.

What MHRA approved actually means

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK regulator for medicines. When a medicine is authorised, it has a licensed indication, approved product information, and a defined framework for how it should be used.

In simple terms, the licence sets the boundaries of appropriate use in the UK. MHRA guidance also says GLP-1 medicines should only be used for their authorised indications and not for aesthetic or cosmetic weight loss.

Which medicines are licensed in the UK for weight management?

As of the review date of this page, MHRA safety communications state that Saxenda (liraglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide) are the GLP-1 or related medicines licensed for weight management in the UK.

Wegovy (semaglutide)

Wegovy is licensed for weight management and is also covered by NICE guidance for NHS use in a specialist weight-management service for certain patients.

Saxenda (liraglutide)

Saxenda is licensed in the UK for weight loss when used with diet and exercise. MHRA safety communications continue to identify it as one of the licensed weight-management medicines.

Mounjaro (tirzepatide)

Mounjaro was authorised by the MHRA in November 2023 for weight management and weight loss in adults with BMI 30 kg/m2 or more, or BMI 27 to 30 kg/m2 with weight-related health problems, to be used alongside a reduced-calorie diet and increased physical activity.

NHS England now includes tirzepatide in its obesity pathway, but rollout is phased rather than immediate for everyone who might be eligible.

Licensed use vs off-label use

Off-label means using a medicine outside its licensed indication or outside the terms of its licence. MHRA guidance says it has not assessed the safety and effectiveness of GLP-1 medicines when used outside their licensed use.

The MHRA also states that these medicines should not be used for purely aesthetic or cosmetic weight loss.

This matters because people sometimes confuse online popularity or social media demand with approved medical use.

Why authorisation does not guarantee access

A medicine can be licensed in the UK without being automatically available to you.

For NHS access, what matters is not just MHRA authorisation but also NICE guidance, commissioning, and local NHS delivery arrangements.

For private access, a licence still does not mean automatic suitability. A legitimate private provider should assess whether treatment is appropriate for you, explain risks and follow-up, and prescribe only within proper clinical and regulatory boundaries.

NHS vs private access

Even when a medicine is licensed:

• NHS access depends on NICE recommendations, local commissioning, and service rollout.
• Private access depends on the provider's clinical model, assessment standards, and whether a prescriber judges the medicine appropriate.

That is why it is usually more helpful to compare pathways and service models than to focus only on the medicine name.

Safety note: counterfeit and unregulated products

The MHRA has warned about unsafe fake weight-loss pens in the UK and says patients should only access these medicines through a legitimate prescription route.

Safer signs include:

• a real clinical consultation
• clear company and pharmacy details
• named or identifiable clinical oversight
• a clear complaints process
• a contactable clinician or clinical team

Safety note: authorised does not mean risk-free

Even for authorised uses, these medicines are not risk-free. Recent MHRA safety updates have highlighted important potential risks that clinicians and patients should be aware of.

That does not mean people should avoid these medicines altogether. It means licensed use still needs proper clinical assessment, monitoring, and good patient information.

Bottom line

MHRA approved means a medicine is licensed in the UK for specific uses. For weight management, the main licensed options are Wegovy, Saxenda, and Mounjaro.

But authorisation is only one part of the picture. Real-world access still depends on clinical suitability, pathway rules, and how care is delivered.

Next reads

Next steps